| WB | 1/200-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | Ckb-6, MPIF2, MPIF-2, SCYA24 |
| WB Predicted band size | 13 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human CCL24 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
1. **"CCL24 neutralization by a monoclonal antibody in primary sclerosing cholangitis"**
*Authors: Liaskou et al.*
摘要：研究报道了一种靶向CCL24的单克隆抗体，通过抑制CCL24介导的免疫细胞趋化作用，减少肝脏纤维化和炎症，为原发性硬化性胆管炎的治疗提供潜在策略。
2. **"Anti-CCL24 antibody-based therapy for fibrotic diseases"**
*Authors: Smith et al.*
摘要：该文献验证了抗CCL24抗体在肺纤维化和肝纤维化模型中的疗效，显示其通过阻断CCL24/CCR3通路抑制成纤维细胞活化及胶原沉积。
3. **"CCL24 as a therapeutic target in atopic dermatitis"**
*Authors: Kim et al.*
摘要：研究表明，抗CCL24单抗可减少皮肤中嗜酸性粒细胞浸润和Th2型炎症反应，缓解小鼠特应性皮炎模型的症状，提示其在过敏性疾病中的治疗潜力。
4. **"Targeting CCL24 in cancer-associated fibrosis"**
*Authors: Garcia et al.*
摘要：研究揭示CCL24在肿瘤微环境中促进纤维化和免疫抑制的作用，使用人源化抗CCL24抗体可改善化疗药物递送并增强抗肿瘤免疫应答。
(注：上述文献为示例，实际文献需通过PubMed或学术数据库检索确认。)
CCL24. also known as eotaxin-2. is a chemokine belonging to the CC subfamily that plays a critical role in immune regulation and inflammatory responses. It binds to the CCR3 receptor, primarily expressed on eosinophils, basophils, and Th2 lymphocytes, facilitating their migration to sites of inflammation or injury. CCL24 is implicated in the pathogenesis of various inflammatory and fibrotic diseases, including asthma, atopic dermatitis, idiopathic pulmonary fibrosis (IPF), and liver fibrosis, where excessive eosinophil recruitment perpetuates tissue damage.
CCL24 antibodies are therapeutic or diagnostic tools designed to specifically target and neutralize CCL24 activity. By blocking CCL24-CCR3 interactions, these antibodies inhibit the chemotaxis of pro-inflammatory cells, thereby reducing chronic inflammation and fibrosis. Monoclonal antibodies against CCL24 have shown promise in preclinical studies, particularly in models of fibrotic disorders and eosinophil-mediated diseases. For instance, they may attenuate collagen deposition in IPF or mitigate allergic responses in asthma.
Additionally, CCL24 overexpression has been linked to certain cancers, where it may promote tumor progression and immunosuppression. Antibodies targeting CCL24 could thus have dual utility in oncology and immunology. Current research focuses on optimizing antibody specificity, pharmacokinetics, and safety profiles, with some candidates advancing to early-phase clinical trials. Overall, CCL24 antibodies represent a potential therapeutic avenue for diseases driven by dysregulated chemokine signaling.
×
